Gus Khursigara
Plus aucun poste en cours
Profil
Gus Khursigara worked as Vice President-Global Medical Affairs at Alexion Pharmaceuticals, Inc. and as VP-Medical Affairs & Clinical Operations at Inozyme Pharma, Inc. He also worked as Vice President-Global Medical Affairs at Biohaven Pharmaceuticals, Inc. from 2018 to 2019.
Mr. Khursigara holds a doctorate degree from Cornell University, an undergraduate degree from the University of California San Diego, and a graduate degree from the University of Connecticut.
Anciens postes connus de Gus Khursigara
| Sociétés | Poste | Fin |
|---|---|---|
Biohaven Pharmaceuticals, Inc.
 Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Directeur Technique/Scientifique/R&D | 01/09/2019 |
| ALEXION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
| INOZYME PHARMA, INC. | Corporate Officer/Principal | - |
Formation de Gus Khursigara
| Cornell University | Doctorate Degree |
| University of Connecticut | Graduate Degree |
| University of California San Diego | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Commercial Services |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |